flowers background. dr.rosen's smiling face at the bottom left. Breast cancer news.

Dr. Barry Rosen Joins SimBioSys as Chief Medical Officer Amidst TumorSight™’s FDA Clearance

SimBioSys, a trailblazing TechBio company renowned for integrating artificial intelligence (AI) and spatial biophysics in cancer precision medicine, recently announced a pivotal development. Dr. Barry Rosen, a distinguished breast surgical oncologist with a quarter-century of clinical experience, and medical advisor to Learn Look Locate has been appointed as their new Chief Medical Officer. This strategic appointment aligns with SimBioSys’s notable achievement of receiving FDA clearance for TumorSight™, their innovative digital precision medicine platform.

Dr. Rosen’s Expertise and Vision for TumorSight™

Dr. Barry Rosen, nationally recognized for his expertise in oncoplastic surgery, brings his vast experience and skillset to SimBioSys. His extensive work in oncoplastic surgery and contributions to the American Society of Breast Surgeons (ASBrS) and other esteemed organizations highlight his dedication to enhancing breast cancer care.

TumorSight™: Revolutionizing Precision Medicine in Cancer Care

The FDA clearance of TumorSight™ marks a significant milestone for SimBioSys. This platform promises to transform cancer patient care by offering precise, tailored treatment solutions. Tushar Pandey, CEO of SimBioSys, shared his enthusiasm about Dr. Rosen’s appointment, emphasizing the crucial timing as they introduce TumorSight™ into the healthcare market and continue their groundbreaking research with PhenoScope™.

Dr. Rosen’s Impact and Vision for Future Cancer Care

Having served as a clinical advisor to SimBioSys for over a year, Dr. Rosen has already made substantial contributions to the company’s development efforts. He likened TumorSight™ to advanced technology used in home remodeling projects, emphasizing the need for such innovation in breast cancer surgery. His vision is to bring a new dimension of understanding and confidence to both physicians and patients in making informed decisions about cancer care.

Learn Look Locate: Supporting Innovations in Cancer Care

In the wake of such groundbreaking advancements in cancer care, Learn Look Locate (LLL) remains committed to bringing the latest in cancer treatment and technology to the forefront. As Dr. Rosen steps into his role with SimBioSys and TumorSight™ gains momentum, LLL continues to support and spotlight innovations that promise a brighter future for cancer patients worldwide.